Neuro-Oncology Reviews
Volume
27 Number 16
10 June 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 16, 10 June
Chen AG, Do TH, Chen KY, Zhu P.
Robust
and Specific Association Between Seizure at Presentation and
Improved Survival in Patients With Primary Brain Tumors.
Discov
Med. 2025 Jun;37(197):984-993. doi:
10.24976/Discov.Med.202537197.88. PMID:
40485516. Review˰ ˍ
Maitra A, Miciaccia M, Mandorino M, Armenise D, Baldelli OM,
Ferorelli S, Papusha L, Druy A, Perrone MG, Scilimati A.
Decoding
Gene Expression Changes in Cerebral Tumors: Before and After
Radiotherapy.
Med
Res Rev. 2025 Jun 1. doi:
10.1002/med.22122. PMID:
40452178. Review. ˍ
>>>
Diffuse midline glioma
Gong AD, Dang DD, Awan O, Mugge L, Yokoi H, Cohen AL, Moores L.
Pediatric-type high-grade glioma of
the spinal cord in the molecular era: institutional case series
and updated systematic review of the literature.
Childs
Nerv Syst. 2025 Jun 2;41(1):200. doi:
10.1007/s00381-025-06856-8. PMID:
40455242. Review˰ ˍ
Liu Y, Su C, Wei X, Wei N, Qian Q, Xu Z.
Prospects
and applications of NK therapy in the treatment of gliomas
(Review).
Oncol
Rep. 2025 Jun 3;54(2):88. doi:
10.3892/or.2025.8921. PMID:
40476557. Review. ˍ
Song Z, Yang C, Gu J, Qu R, Xie Y, Guo Y, Nong X, Chen Z, Wang Z.
The hotspots and publication trends in
glioblastoma and CAR-T immunotherapy: A bibliometric analysis.
Hum
Vaccin Immunother. 2025 Jun 3;21(1):2509483. doi:
10.1080/21645515.2025.2509483. PMID:
40460258. Bibliometric analysis. ˍ
Feng XL, Su G, Wu QH, Jia Q, Zhang ZC.
Research
progress of galectins in glioma.
Discov
Oncol. 2025 Jun 4;16(1):1003. doi:
10.1007/s12672-025-02318-4. PMID:
40467873. Review. ˍ
Shah S, Lucke-Wold B.
Cell-Intrinsic
and Cell-Extrinsic Therapeutic Targets in Glioblastoma: Overcoming
Resistance Through Tumor Microenvironment Modulation and Precision
Medicine.
World
Neurosurg. 2025 Jun 4:124142. doi:
10.1016/j.wneu.2025.124142. PMID:
40480545. Review. ˍ
Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, Zheng Y, Ye C, Li F, Ge S,
Yao A, Jia L.
Overcoming temozolomide
resistance in glioma: recent advances and mechanistic insights.
Acta
Neuropathol Commun. 2025 Jun 5;13(1):126. doi:
10.1186/s40478-025-02046-4. PMID:
40468460. Review. ˍ
Aman R, Desbassarie F, Lubis AR, Ardiansyah IR.
Prognostic
factors and survival of recurrent glioblastoma: a systematic
review.
Folia
Med (Plovdiv). 2025 Jun 6;67(3). doi:
10.3897/folmed.67.e142227. PMID:
40524591. Review. ˍ
Doniselli FM, Ramos J, Hilario A, Opancina V, van der Hoorn A,
Castellano A, van der Molen AJ, Quattrocchi CC, Yousry T, Rovira
À; ESMRMB-GREC Working Group; ESNR.
Recommendations
on the use of gadolinium-based contrast agents in the diagnosis
and monitoring of common adult intracranial tumours.
Eur
Radiol. 2025 Jun 6. doi:
10.1007/s00330-025-11646-6. PMID:
40478344. Recommendations˰
ˍ
Qiu Y, Huang S, Peng L, Yang L, Zhang G, Liu T, Yan F, Peng X.
The Nasal-Brain Drug Delivery Route:
Mechanisms and Applications to Central Nervous System Diseases.
MedComm
(2020). 2025 Jun 6;6(6):e70213. doi:
10.1002/mco2.70213. PMID:
40487748. Review. ˍ
Rudà R, Bruno F, Pellerino A, Pronello E, Soffietti R.
Low-grade IDH-mutant
gliomas: from standard post-surgical treatments to novel IDH
inhibitors.
Expert
Opin Pharmacother. 2025 Jun 6:1-13. doi:
10.1080/14656566.2025.2516617. PMID:
40479721. Review˰ ˍ
He J, Yan X, Hu S.
Glioma stem cells:
drivers of tumor progression and recurrence.
Stem
Cell Res Ther. 2025 Jun 7;16(1):293. doi:
10.1186/s13287-025-04352-z. PMID:
40483525. Review. ˍ